Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual Property
07. Februar 2019 07:00 ET
|
Harrow Health, Inc.
SAN DIEGO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), today announced that its subsidiary, Mayfield Pharmaceuticals, Inc., has acquired drug formulation assets and...
Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary
05. Februar 2019 07:00 ET
|
Harrow Health, Inc.; Melt Pharmaceuticals, Inc.
SAN DIEGO and BOSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., an affiliated company of Harrow Health, Inc. (NASDAQ: HROW), today announced it has entered into definitive stock...
Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc.
31. Dezember 2018 07:00 ET
|
Harrow Health, Inc.
SAN DIEGO, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (formerly known as Imprimis Pharmaceuticals, Inc.) (NASDAQ: IMMY) announced it has formally changed its name and that it will trade...
Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™
16. November 2018 07:30 ET
|
Imprimis Pharmaceuticals, Inc.
Imprimis attributes growth to its vision of making sure patients have access to high quality affordable medications SAN DIEGO, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc....
Imprimis Pharmaceuticals Announces Third Quarter 2018 Results
13. November 2018 16:01 ET
|
Imprimis Pharmaceuticals, Inc.
SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the third quarter 2018. Third Quarter 2018 and Other Recent Notable Highlights:...
Imprimis Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 13, 2018
06. November 2018 07:00 ET
|
Imprimis Pharmaceuticals, Inc.
SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced it will release third quarter 2018 financial results after the close of trading on Tuesday,...
Imprimis Pharmaceuticals’ Subsidiary Melt Pharmaceuticals Initiates Clinical Development Program for its Patented Non-Opioid and Non-Invasive MK Melt™ Conscious Sedation Drug Candidate
23. Oktober 2018 07:00 ET
|
Imprimis Pharmaceuticals, Inc.; Melt Pharmaceuticals, Inc.
FDA Grants Pre-IND Meeting; Two Investigator-led Studies on Melt Formulations to Commence in Q4 SAN DIEGO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, a subsidiary of Imprimis...
ImprimisRx to feature new formulation and poster presentation on MKO Melt® at the upcoming American Academy of Ophthalmology Meeting in Chicago
16. Oktober 2018 07:00 ET
|
Imprimis Pharmaceuticals, Inc.
Poster on data from a 611-patient study featuring Imprimis’s MKO Melt to be presented SAN DIEGO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- ImprimisRx, the ophthalmic-focused division of Imprimis...
Imprimis Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 6, 2018
31. Juli 2018 07:30 ET
|
Imprimis Pharmaceuticals, Inc.
SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced it will release second quarter 2018 financial results after the close of trading on Monday,...